<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5152">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01166763</url>
  </required_header>
  <id_info>
    <org_study_id>11657</org_study_id>
    <nct_id>NCT01166763</nct_id>
  </id_info>
  <brief_title>Modulation of Breast Cancer Risk Biomarkers by High Dose Vitamin D</brief_title>
  <official_title>Modulation of Breast Cancer Risk Biomarkers by High Dose Vitamin D</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carol Fabian, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BTR Group</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this project is to determine if high dose vitamin D3 given to
      premenopausal women at high risk for development of breast cancer, who initially have
      insufficient levels of 25-hydroxy vitamin D (&lt;30 ng/ml), will raise 25(OH)D levels above 50
      ng/ml. If so, will certain risk biomarkers for development of breast cancer be reliably and
      favorably modulated?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Protocol Objectives:

      To determine if high dose vitamin D3 given to premenopausal women who initially have
      insufficient levels of 25-hydroxy vitamin D (&lt;30 ng/ml) will raise 25(OH)D levels above the
      50 ng/ml level considered to be required for breast health. If so, will certain risk
      biomarkers for development of breast cancer be reliably and favorably modulated? The primary
      endpoint will be a decrease in mammographic breast density (percent area considered at
      increased density). Change in proliferation (a decrease as assessed by Ki-67) will also be
      examined. Modulate of expression of genes important in breast cancer risk or reflective of
      vitamin D's mechanism of action will be studied using quantitative real time polymerase
      chain reaction (qRT-PCR).

      Study Design:

      The study is a single-arm open label clinical trial. Women who are high risk for development
      of breast cancer on the basis of family or personal history will undergo random periareolar
      fine needle aspiration (RPFNA) to acquire breast cells for assessment of gene expression by
      qRT-PCR. Women with mammographic density &gt;10% will be eligible for enrollment. All subjects
      will receive high dose vitamin D3 (3 capsules of 10,000 IU of vitamin D3 every week for 6-8
      months). At that time, a repeat RPFNA and mammogram will be performed. Measurement of serum
      levels of 25(OH)D will be performed at baseline, 3 months, and 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Change in Mammographic Breast Density Over Course of Study</measure>
    <time_frame>baseline and 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in the percent of the breast area that is considered to be at higher density on mammogram.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Proliferation (as Assessed by Ki-67) Examined in Breast Epithelial Cells.</measure>
    <time_frame>baseline and 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in percent of cells expressing staining for Ki-67 antibody in breast epithelial cell specimens acquird by RPFNA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OH Vitamin D Levels in Serum</measure>
    <time_frame>baseline, 3, and 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment of 25(OH)D levels as a measure of circulating vitamin D.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>high dose vitamin D3 (10,000 IU weekly)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group/Cohort Label vitamin D3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vitamin D3</intervention_name>
    <description>oral capsules, 10,000 IU per week for 6 months</description>
    <arm_group_label>high dose vitamin D3 (10,000 IU weekly)</arm_group_label>
    <other_name>Maximum D3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be premenopausal women age 55 or younger, and actively menstruating
             with 4 or more periods per year.

          -  Subjects may be using barrier contraceptive, an intrauterine device, a Nuvaring, or
             similar non-oral contraceptive; or oral contraceptives.

          -  Subjects must be at increased risk for breast cancer on the basis of at least one of
             the following criteria:

               -  five-year Gail risk of 3X the average risk of the age group;

               -  a first degree relative with breast cancer under the age of 60 or multiple
                  second degree relatives with breast cancer;

               -  prior biopsy exhibiting atypical hyperplasia (AH), LCIS, DCIS, RPFNA evidence of
                  hyperplasia with atypia within the last three years;

               -  Chest or neck radiation before age 30;

               -  Breast density equals or exceeds 50 percent.

          -  If previously on a chemoprevention agent or prevention trial, subjects must have
             completed study participation at least 6 months prior to baseline biomarker
             assessment.

          -  If subject has a history of AH, LCIS, or ER-positive DCIS by diagnostic biopsy, must
             have been counseled about appropriate standard prevention therapies such as tamoxifen
             and is either not eligible or is not interested in standard prevention therapies.
             Women with DCIS must have had appropriate local therapy (lumpectomy plus radiation or
             mastectomy).

          -  Subject must have had a mammogram performed at the University of Kansas Breast
             Imaging Center with estimated visual breast density of greater than 10 percent.

          -  Subject must have had within six months prior to entering the study, an RPFNA during
             the follicular portion (day 1-10) of the menstrual cycle with material for
             cytomorphology, Ki-67 and qRT-PCR; in addition to serum obtained and banked.

          -  Subjects must have 25(OH)D level &lt; 30 ng/ml as measured within 8 weeks of starting
             intervention. Subjects may have been identified as having low vitamin D levels
             through participation in HSC 11313, Osteopenia/Osteoporosis in Pre-menopausal Women
             at High Risk for Development of Breast Cancer, but low level must be confirmed within
             8 weeks prior to starting study agent Subject must be willing to continue the same
             hormonal milieu present at baseline throughout trial.

          -  Subjects must be willing to undergo measurement of height, weight, and BMI at
             initiation of intervention.

          -  Subjects must have participated in HSC 11313, and have had a DEXA scan for bone
             density and body fat analysis on the GE Lunar Prodigy Advance research unit in the
             Breast Cancer Survivorship Center.

          -  Subjects must be willing to sign an informed consent for the entire study and
             separate consent for repeat RPFNA.

        Exclusion Criteria:

          -  Women that have had a metastatic malignancy of any kind.

          -  Women that have had prior invasive breast cancer If subject has had a DCIS, at least
             two months must have elapsed from surgery and/or radiation therapy to the involved
             breast. Only the contra-lateral (uninvolved breast) will be studied by FNA. The
             subject may not have had any radiation therapy to the contra-lateral breast to be
             studied.

          -  Women who are pregnant or nursing.

          -  Women who have taken a SERM, aromatase inhibitor or participated in a chemoprevention
             or other investigational drug study within six months prior to baseline FNA.

          -  Women who have used fertility drugs within six months prior to baseline aspiration.

          -  Women with a history of sarcoidosis, hypercalcemia, hyperparathyroidism, or renal
             stones.

          -  Women who are receiving treatment for rheumatoid arthritis or other connective tissue
             diseases.

          -  Women who have an elevated blood calcium level at baseline; defined as any elevation
             above the institutional normal range.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carol Fabian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 30, 2015</lastchanged_date>
  <firstreceived_date>July 16, 2010</firstreceived_date>
  <firstreceived_results_date>January 27, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center Research Institute</investigator_affiliation>
    <investigator_full_name>Carol Fabian, MD</investigator_full_name>
    <investigator_title>Professor, Director Breast Cancer Prevention Unit</investigator_title>
  </responsible_party>
  <keyword>breast atypia</keyword>
  <keyword>high risk for breast cancer</keyword>
  <keyword>random periareolar fine needle aspiration</keyword>
  <keyword>RPFNA</keyword>
  <keyword>breast epithelial hyperplasia</keyword>
  <keyword>ki-67</keyword>
  <keyword>chemoprevention</keyword>
  <keyword>vitamin D3</keyword>
  <keyword>Additional relevant MeSH terms:</keyword>
  <keyword>Molecular Mechanisms of Pharmacological Action</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>Breast Neoplasms</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>Hyperplasia</keyword>
  <keyword>high risk for development of breast cancer</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Neoplasms by Site</keyword>
  <keyword>Pathologic Processes</keyword>
  <keyword>Antirheumatic Agents</keyword>
  <keyword>Breast Diseases</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Molecular Mechanisms of Pharmacological Action</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment April 2009 to December 2010. Breast Cancer Prevetnion Center at University of Kansas Medical Center</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>High Dose Vitamin D3 (10,000 IU Weekly)</title>
          <description>Group/Cohort Label vitamin D3
vitamin D3: oral capsules, 10,000 IU per week for 6 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>High Dose Vitamin D3 (10,000 IU Weekly)</title>
          <description>Group/Cohort Label vitamin D3
vitamin D3: oral capsules, 10,000 IU per week for 6 months</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="41.4" spread="4.9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="28"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Not Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="28"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gail Risk 5-year Probability of Cancer Development</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="1.6" spread="1.2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Mammographic Breast Density Over Course of Study</title>
        <description>Change in the percent of the breast area that is considered to be at higher density on mammogram.</description>
        <time_frame>baseline and 6 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All subjects completing trial</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D3 (10,000 IU Weekly)</title>
            <description>Group/Cohort Label vitamin D3
vitamin D3: oral capsules, 10,000 IU per week for 6 months</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Mammographic Breast Density Over Course of Study</title>
            <description>Change in the percent of the breast area that is considered to be at higher density on mammogram.</description>
            <units>Change in percent dense breast area</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-0.5" spread="5.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Proliferation (as Assessed by Ki-67) Examined in Breast Epithelial Cells.</title>
        <description>Change in percent of cells expressing staining for Ki-67 antibody in breast epithelial cell specimens acquird by RPFNA.</description>
        <time_frame>baseline and 6 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All subjects completing trial.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D3 (10,000 IU Weekly)</title>
            <description>Group/Cohort Label vitamin D3
vitamin D3: oral capsules, 10,000 IU per week for 6 months</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Proliferation (as Assessed by Ki-67) Examined in Breast Epithelial Cells.</title>
            <description>Change in percent of cells expressing staining for Ki-67 antibody in breast epithelial cell specimens acquird by RPFNA.</description>
            <units>percentage of cells staining positive</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-0.4" lower_limit="-4.0" upper_limit="4.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OH Vitamin D Levels in Serum</title>
        <description>Assessment of 25(OH)D levels as a measure of circulating vitamin D.</description>
        <time_frame>baseline, 3, and 6 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All subjects completing trial</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D3 (10,000 IU Weekly)</title>
            <description>Group/Cohort Label vitamin D3
vitamin D3: oral capsules, 10,000 IU per week for 6 months</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>OH Vitamin D Levels in Serum</title>
            <description>Assessment of 25(OH)D levels as a measure of circulating vitamin D.</description>
            <units>ng/ml 25(OH)D at 6 months</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="55.4" spread="13.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months duration of study agent administration</time_frame>
      <group_list>
        <group group_id="E1">
          <title>High Dose Vitamin D3 (10,000 IU Weekly)</title>
          <description>Group/Cohort Label vitamin D3
vitamin D3: oral capsules, 10,000 IU per week for 6 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTC 4</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <description>Grade 3, considered not to be related to study agent.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Increase in diarrhea</sub_title>
                <description>Grade 3, not considered to be related to study agent.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Flank pain</sub_title>
                <description>Grade 3 flank pain, not considered to be related to study agent</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTC 4</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal cramps</sub_title>
                <description>Grade 2 (2 instances in same subject)</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Grade 2 headache</description>
                <counts group_id="E1" events="30" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Single arm pilot trial so all comparisons are within subject for change over the course of the study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Bruce F. Kimler, Ph.D.</name_or_title>
      <organization>University of Kansas Medical Center</organization>
      <phone>913-588-4523</phone>
      <email>bkimler@kumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
